Registrational Phase 3 study for advanced melanoma immunotherapy delivered with PharmaJet's IM Needle-free System planned for ...

Diorasis Therapeutics, a Boston-based biotechnology company developing durable gene therapies for glaucoma and other ...

Enthorin Therapeutics, LLC, a biotechnology company focused on circuit-modulating treatments for neurological and neurodevelopmental disorders, announced that its licensing partner for MRM-3379 ...

Health system pharmacists and clinicians are monitoring a wave of drug approvals expected throughout 2026, including first-in-class therapies and expanded uses of existing drugs with implications for ...

Panther is inviting pharmaceutical and biotechnology partners to co-develop higher-efficacy, lower-toxicity, shelf-stable therapies using its MAP platform. We believe rethinking how treatments are ...

Foster Mohale from the National Department of Health this week confirmed that there are no national policies or regulations ...

Camurus (NASDAQ STO: CAMX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's resubmission of the New Drug Application (NDA) for Oclaiz™ (CAM2029), ...

Sadly, the number of young people dying through drug overdoses is also increasing in B.C., with drug poisoning being the ...